| Literature DB >> 24588984 |
Siri Tandberg Nygård, Nina Langeland, Hans K Flaatten, Rune Fanebust, Oddbjørn Haugen, Steinar Skrede1.
Abstract
BACKGROUND: Severe sepsis is recognized as an inflammatory response causing organ dysfunction in patients with infection. Antimicrobial therapy is the mainstay of treatment. There is an ongoing demand for local surveillance of sepsis aetiology and monitoring of empirical treatment recommendations. The present study was established to describe the characteristics, quality of handling and outcome of patients with severe sepsis admitted to a Norwegian university hospital.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24588984 PMCID: PMC3975934 DOI: 10.1186/1471-2334-14-121
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Suspected, confirmed and proportion of correct identified focus of infection in community acquired severe sepsis (n (%))
| Respiratory | 101 (45.9) | 115 (52.3) | 93 (80.9) |
| Genitourinary | 25 (11.4) | 31 (14.1) | 20 (64.5) |
| Soft tissue | 23 (10.5) | 27 (12.3) | 18 (66.7) |
| Abdominal | 16 (7.3) | 26 (11.8) | 13 (50) |
| Endocarditis | 4 (1.8) | 12 (5.5) | 4 (33.3) |
| Bacteremia | 2 (0.9) | 5 (2.3) | 1 [ |
| CNS | 4 (1.8) | 4 (1.8) | 2 (50) |
| Unknown | 36 (16.4) | 0 (0.0) | n.a. |
| Not suspected | 9 (4.1) | n.a. | n.a. |
| Total | 220 (100) | 220 (100) | 151 (68.6) |
Abbreviations: CNS, central nervous system; n.a., not applicable.
aPercent calculated column-wise, from total cases.
bPercent calculated row-wise, from each infection category’s total number of confirmed cases.
Microbiological aetiology in community acquired severe sepsis (n)
| 90 | 44 | 27 | 25 | 18 | |
| 29 | 14 | 20b | 0 | 5 | |
| 18 | 7 | 0 | 6 | 7 | |
| 13 | 6 | 0 | 9 | 1 | |
| 2 | 1 | 0 | 1 | 0 | |
| 6 | 3 | 2 | 0 | 2 | |
| 20 | 11 | 4 | 9 | 3 | |
| 1 | 1 | 0 | 0 | 0 | |
| 1 | 1 | 1 | 0 | 0 | |
| 55 | 32 | 21 | 8 | 9 | |
| 27 | 19 | 13 | 3 | 3 | |
| 10 | 6 | 5 | 0 | 1 | |
| 1 | 1 | 0 | 0 | 0 | |
| 2 | 0 | 0 | 1 | 1 | |
| 5 | 2 | 3 | 1 | 0 | |
| 2 | 1 | 0 | 1 | 1 | |
| 1 | 0 | 0 | 1 | 0 | |
| 2 | 2 | 0 | 0 | 0 | |
| 2 | 1 | 0 | 0 | 1 | |
| 2 | 0 | 0 | 0 | 2 | |
| 1 | 0 | 0 | 1 | 0 | |
| 17 | 6 | 0 | 3 | 9 | |
| 5 | 2 | 0 | 0 | 3c | |
| 5 | 3 | 0 | 1 | 2 | |
| 4 | 0 | 0 | 2 | 2 | |
| 1 | 1 | 0 | 0 | 0 | |
| 1 | 0 | 0 | 0 | 1 | |
| 1 | 0 | 0 | 0 | 1 | |
| 9 | 0 | 0 | 3 | 6 | |
| 7 | 0 | 0 | 3 | 4 | |
| 1 | 0 | 0 | 0 | 1 | |
| 1 | 0 | 0 | 0 | 1 | |
| 129 | 74 | 40 | 23 | 29 |
Unless otherwise specified, numbers shown are all isolated microorganisms in category.
aAnaerobic species not included.
bPositive antigen tests in all 20 cases (14 cases were detected in antigen tests only).
cDetection of Clostridium difficile toxin A in all cases.
Figure 1Microbiological identification rates in different infection categories (n). Relationship between focus of infection and the proportion of patients with confirmed microbiological aetiology. The most prevalent microbe was in RTI (respiratory tract infection); Streptococcus pneumoniae (28/43), GUI (genitourinary infection); Escherichia coli (16/28), STI (soft tissue infection); Group A/C/G streptococci (10/23), ABD (abdominal infection); Escherichia coli (8/15), and AIE (acute infectious endocarditis); Staphylococcus aureus (5/12).
Choice of empirical antimicrobial regimen according to suspected and confirmed focus of infection and compliance with recommendations (n/n (%))
| 100d/82 (82.0) | 115d/96 (83.5) | |
| 25d/20 (80.0) | 30d/24 (80.0) | |
| 23/18 (78.3) | 27d/18 (66.7) | |
| 16d/11 (68.8) | 26d/13 (50.0) | |
| 4/3 (75.0) | 12/7 (58.3) | |
| 4/3 (75.0) | 4/4 (100) | |
| 38d/34 (89.5) | 5/5 (100) | |
| 210/171 (81.4) | 219/167 (76.3) |
aCorrect and appropriate regimen according to recommendations for empirical antimicrobial therapy in Haukeland University Hospital in 2008.
bOne patient with a suspected and later verified respiratory tract infection died before antimicrobial therapy was implemented.
cSuspected atypical pneumonia: macrolide or doxycycline is added.
dNumber of correct cases including one patient given meropenem as initial agent (n = 4 in total).
eIf allergic to penicillin: clindamycin.
fIf gentamicin is contraindicated: 3rd generation cephalosporin monotherapy.
In-hospital mortality in patients with community acquired severe sepsis at Haukeland University Hospital in 2008
| | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gender | | | | | | 0.240 | | | | | | |
| Male | 117 | 33 | (28.2) | 1.00 | Reference | | | | | | | |
| Female | 103 | 22 | (21.4) | 0.69 | (0.37, 1.29) | | | | | | | |
| Age (years) | | | | | | 0.065 | | | 0.619 | | | |
| 16-30 | 18 | 1 | (5.6) | 1.00 | Reference | | 1.00 | Reference | | | | |
| 30-45 | 22 | 4 | (18.2) | 3.78 | (0.38, 37.28) | | 0.99 | (0.07, 14.18) | | | | |
| 45-60 | 36 | 8 | (22.2) | 4.86 | (0.56, 42.30) | | 2.27 | (0.19, 26.64) | | | | |
| 60-75 | 68 | 16 | (23.5) | 5.23 | (0.65, 42.43) | | 2.88 | (0.28, 29.54) | | | | |
| ≥75 | 76 | 26 | (34.2) | 8.84 | (1.11, 70.18) | | 3.09 | (0.28, 33.54) | | | | |
| Comorbidity | | | | | | | | | | | | |
| None | 23 | 1 | (4.3) | 0.12 | (0.02, 0.92) | 0.005 | | | | | | |
| Hypertension | 91 | 18 | (19.8) | 0.61 | (0.32, 1.17) | 0.130 | | | | | | |
| Cardiovascular | 107 | 35 | (32.7) | 2.26 | (1.20, 4.24) | 0.010 | 2.18 | (0.85, 5.61) | 0.101 | 3.29 | (1.45, 7.48) | 0.003 |
| Pulmonary | 61 | 14 | (23.0) | 0.86 | (0.43, 1.72) | 0.662 | | | | | | |
| Diabetes | 38 | 9 | (23.7) | 0.92 | (0.40, 2.08) | 0.836 | | | | | | |
| Malignancy | 31 | 13 | (41.9) | 2.53 | (1.15, 5.58) | 0.025 | 5.97 | (1.96, 18.19) | 0.001 | 5.50 | (1.92, 15.78) | 0.001 |
| Dementia | 17 | 6 | (35.3) | 1.71 | (0.60, 4.88) | 0.324 | | | | | | |
| Psychiatric | 51 | 9 | (17.6) | 0.57 | (0.26, 1.27) | 0.155 | | | | | | |
| Substance abuse | 31 | 6 | (19.4) | 0.69 | (0.27, 1.77) | 0.423 | | | | | | |
| Otherd | 74 | 27 | (36.5) | 2.42 | (1.29, 4.53) | 0.006 | 2.52 | (1.11, 5.70) | 0.025 | 2.43 | (1.10, 5.35) | 0.026 |
| Correct suspected focus of infection | | | | | | 0.020 | | | 0.606 | | | |
| Yes | 152 | 31 | (20.4) | 1.00 | Reference | | 1.00 | Reference | | | | |
| No | 68 | 24 | (35.3) | 2.13 | (1.13, 4.02) | | 0.79 | (0.33, 1.91) | | | | |
| Confirmed focus of infection | | | | | | 0.007 | | | 0.003 | | | 0.001 |
| Respiratory | 115 | 25 | (21.7) | 1.00 | Reference | | 1.00 | Reference | | | | |
| Genitourinary | 31 | 4 | (12.9) | 0.53 | (0.17, 1.67) | | 0.41 | (0.08, 2.21) | | 0.47 | (0.09, 2.39) | |
| Soft tissue | 27 | 6 | (22.2) | 1.03 | (0.38, 2.82) | | 2.04 | (0.55, 7.60) | | 2.42 | (0.68, 8.68) | |
| Abdominal | 26 | 12 | (46.2) | 3.09 | (1.27, 7.51) | | 2.95 | (0.87, 10.03) | | 3.54 | (1.09, 11.43) | |
| Endocarditis | 12 | 7 | (58.3) | 5.04 | (1.47, 17.25) | | 17.43 | (2.74, 111.06) | | 18.94 | (3.45, 104.06) | |
| Bacteremia | 5 | 0 | (0.0) | 0.00 | (0.00, ) | | 0.00 | (0.00, ) | | 0.00 | (0.00, ) | |
| CNS | 4 | 1 | (25.0) | 1.20 | (0.12, 12.04) | | 9.22 | (0.71, 118.97) | | 7.66 | (0.63, 93.73) | |
| Microbiological samples | | | | | | 0.008 | | | 0.028 | | | 0.025 |
| Positive | 129 | 24 | (18.6) | 1.00 | Reference | | 1.00 | Reference | | 1.00 | Reference | |
| Negative | 83 | 26 | (31.3) | 2.00 | (1.05, 3.79) | | 3.58 | (1.34, 9.55) | | 3.34 | (1.29, 8.63) | |
| Not obtained | 8 | 5 | (62.5) | 7.29 | (1.63, 32.63) | | 2.91 | (0.35, 24.09) | | 4.44 | (0.60, 32.95) | |
| Empirical antimicrobial agents | | | | | | | | | | | | |
| Suspected focus of infection | | | | | | 0.433 | | | | | | |
| | 171 | 38 | (22.2) | 1.00 | Reference | | | | | | | |
| | 39 | 11 | (28.2) | 1.38 | (0.63, 3.02) | | | | | | | |
| Confirmed focus of infection | | | | | | 0.027 | | | 0.241 | | | |
| | 168 | 35 | (21.0) | 1.00 | Reference | | 1.00 | Reference | | | | |
| | 52 | 19 | (36.5) | 2.17 | (1.10, 4.27) | | 0.79 | (0.33, 1.91) | | | | |
| Microbiological aetiologye | | | | | | < 0.001 | | | | | | |
| | 106 | 12 | (11.3) | 1.00 | Reference | | | | | | | |
| | 23 | 12 | (52.2) | 8.55 | (3.10, 23.58) | | | | | | | |
| In-hospital initial dose administered | | | | | | 0.002 | | | 0.051 | | | 0.046 |
| | 157 | 30 | (19.1) | 1.00 | Reference | | 1.00 | Reference | | 1.00 | Reference | |
| ≥ | 54 | 22 | (40.7) | 2.91 | (1.49, 5.71) | | 2.52 | (1.00, 6.38) | | 2.48 | (1.02, 6.02) | |
| Pre-hospital administration | | | | | | 0.059 | | | 0.055 | | | 0.041 |
| | 205 | 48 | (23.4) | 1.00 | Reference | | 1.00 | Reference | | 1.00 | Reference | |
| | 15 | 7 | (46.7) | 2.86 | (0.99, 8.30) | 4.13 | (0.99, 17.21) | 4.20 | (1.08, 16.39) | |||
Abbreviations: OR: odds ratio; CI: confidence interval.
an = 220.
bIncludes all categories with P < 0.10 in the unadjusted analyses; n = 211; Hosmer-Lemeshow’s chi-square = 12.38, df = 8, P = 0.135.
cFrom backward stepwise selection at significance level 0.05; n = 211; Hosmer-Lemeshow’s chi-square = 3.18, df = 8, P = 0.923.
dIncluding chronic kidney, liver and rheumatic diseases.
eNot included in multivariate analysis due to a substantial number of not applicable cases (if included, significant in multivariate analysis).
Figure 2Long-term survival after community acquired severe sepsis. Kaplan-Meier curve on survival after community acquired severe sepsis in different age groups. Follow-up was four years after hospital admission for all 220 patients. Survival in all three groups were significant different according to Log rank test results (P = 0.000 in analysis of age group 16–50 vs. 50–75 and P = 0.001 in analysis of age group 50–75 vs. ≥75). Overall, four-year mortality was 55.5%.